

Trial of local anaesthetic nerve blocks for hip fracture pain relief in prehospital care, compared to usual care (morphine), given by paramedics

Submission date 05/11/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 22/09/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 19/08/2022	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Hip fractures are a very common injury for elderly people. About one in three patients who break their hip die within one year and many patients lose mobility and independence. Pain relief before the patient reaches hospital is often inadequate and causes side effects which may slow down recovery. We have recently completed a small study testing whether a local anaesthetic injection into the hip area called Fascia Iliaca Compartment Block (FICB) given by paramedics at the scene of injury is safe and acceptable. We met all the criteria that we set at the beginning of the study, and concluded that it is feasible to undertake a full trial.

Aim

We aim to find out whether the local anaesthetic injection reduces pain, is safe, and improves patient health outcomes, as well as how much it costs the National Health Service (NHS).

Who can participate?

Adult patients attended by a participating study paramedic following a 999 call who are assessed as having an isolated hip fracture.

What does the study involve?

We will carry out a trial where paramedics give patients either the new treatment - local anaesthetic injection or usual care (often morphine). Patients will be allocated to one or other treatment by a random process (similar to tossing a coin) to ensure a fair comparison between treatments.

We will provide training for the paramedics who take part in the trial, so that they can perform the local anaesthetic injection safely. When a trained paramedic attends a patient he or she assesses as having a hip fracture, (s)he will use a scratchcard to decide which treatment to give the patient. We will compare patients' pain levels, other outcomes and costs between those allocated to the new local anaesthetic injection and those allocated to receive usual care. The other outcomes we will compare between the two groups during their initial care and up to four

months following injury are: length of stay in hospital, deaths, quality of life, ability to walk, and satisfaction with care. We will also monitor safety by identifying any concerning health-related events in each group. We will work out the costs of NHS care in each group.

What are the possible benefits and risks of participating?

The possible benefits of taking part are potentially receiving more effective pain relief at the time of hip fracture. The risks of taking part - there are some potential complications of the local anaesthetic nerve block, including infection or bruising at the site of the injection. Rarer complications include nerve damage and local anaesthetic toxicity. Although there are potential complications, current usual care (morphine) also has several known side effects including confusion, nausea, constipation and respiratory depression - the patient will avoid these side effects.

Patient and public involvement

Two members of the public have helped us to plan this bid and two patient groups (approximately 40 individuals) reviewed our ideas. Members of the public will continue to be involved throughout this research. During the research, members of the public will attend meetings, help to write information sheets for patients, and help to write up the findings from this research. Members of the public will also sit on our oversight committee to ensure the research is carried out properly, and be part of local implementation teams at sites to ensure the patient voice is heard throughout our research.

Where is the study run from?

Swansea University and areas within five ambulance services in England and Wales.

When is the study starting and how long is it expected to run for?

June 2020 to January 2025.

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Dr Jenna Jones

j.k.jones@swansea.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Jenna Jones

ORCID ID

<http://orcid.org/0000-0002-1280-4941>

Contact details

ILS2 Singleton Campus

Swansea University

Swansea

United Kingdom

SA2 8PP
+44 (0)1792513424
j.k.jones@swansea.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

291853

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 47827, NIHR 129972, IRAS 291853

Study information

Scientific Title

Randomised trial of clinical and cost effectiveness of Administration of Prehospital fascia Iliaca compartment block for emergency hip fracture care Delivery (RAPID2)

Acronym

RAPID2

Study objectives

FICB provides better pain relief for patients with hip fracture in prehospital care than morphine

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multi-site parallel group superiority randomized trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Community

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Pain relief of patients with hip fracture in prehospital care

Interventions

Usual care

Currently, when a patient who has called 999 is attended by a paramedic for a suspected hip fracture, the paramedic clinically assesses the patient, takes their history, examines them and records observations (blood pressure, heart rate, respiratory rate, oxygen saturations, Glasgow Coma Scale, patient reported pain score and temperature). Paramedics cannulate patients and provide IV fluids and/or oxygen, as appropriate, based on clinical parameters. They are currently able to provide systemic analgesia only, most commonly opioids (IV morphine), paracetamol and Entonox. In RAPID 2, patients allocated to usual care, will receive this care.

Intervention care

If the patient is randomly allocated to the intervention arm, the paramedic will administer FICB in addition to basic usual care as described above, but avoiding use of opioids. The FICB will utilise 1% Prilocaine and will follow the method used in the RAPID feasibility study (<http://www.isrctn.com/ISRCTN60065373>) (based on Dalens et al 1989). The paramedic will still provide the patient with paracetamol and Entonox but should not give the patient morphine for at least 20 minutes after the patient has received the FICB (to allow for the time of onset of Prilocaine). If, however, the FICB does not relieve the patient's pain after 20 minutes, the paramedic would be able to give the patient morphine if judged appropriate ('rescue morphine').

Random allocation is carried out using sequentially numbered unique scratchcards, out of the sight of the patient. Both study arms will be followed up at one and four months.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

1% Prilocaine

Primary outcome measure

Pain measured using an eleven point numeric rating scale (0-10) pre-randomisation and on arrival at the emergency department

Secondary outcome measures

1. Routine data taken from patient records:

1.1. Ambulance service job cycle time (from 999 call to 'ambulance free')

1.2. Analgesia and anti-emetics administered prehospitally, including morphine and 'rescue morphine'

1.3. Length of stay in hospital, ITU and residential rehabilitation care following injury

- 1.4. Subsequent ED attendances and emergency admissions
- 1.5. Mortality
- 1.6. Diagnosis (for patients who did not have a hip fracture)
- 1.7. Where patient was admitted from and discharged to
2. Patient-reported outcomes:
 - 2.1. Satisfaction with care (Quality of Care Monitor at one month)
 - 2.2. Health related quality of life (HRQoL) (EQ-5D-5L at one and four months)
 - 2.3. Mobility (Rivermead Mobility Index at one and four months. One question will be removed to enable to patient to complete the questionnaire by themselves)
3. Costs to the NHS: This includes all the costs (excluding research costs) sustained to deliver the intervention. A purposely designed data collection questionnaire tested in the feasibility study will be sent to each recruiting site at the end of the study

Overall study start date

10/06/2020

Completion date

31/01/2025

Eligibility

Key inclusion criteria

Adult patients attended by a participating study paramedic following a 999 call who are:

1. Assessed as having an isolated hip fracture – hip fracture assessment checklists will be provided to aid recognition
2. Conscious (Glasgow Coma Scale Score of ≥ 13)
3. Haemodynamically stable
4. To be conveyed to a participating receiving hospital

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

1,404

Key exclusion criteria

1. Taking anticoagulants
2. Have a hip prosthesis on the affected side
3. Refuse analgesia
4. Are thought to be having a stroke
5. Are combative
6. Are attended by a paramedic working alone

Date of first enrolment

01/10/2021

Date of final enrolment

30/09/2023

Locations

Countries of recruitment

England

United Kingdom

Wales

Study participating centre

East of England Ambulance Service

United Kingdom

SG8 6EN

Study participating centre

East Midlands Ambulance Service

United Kingdom

NG8 6PY

Study participating centre

South East Coast Ambulance Service

United Kingdom

RH10 9BG

Study participating centre

South West Ambulance Service

United Kingdom

EX2 7HY

Study participating centre

Welsh Ambulance Service

United Kingdom

LL17 0LJ

Study participating centre

Addenbrooke's Hospital

Hills Road
Cambridge
United Kingdom
CB2 0QQ

Study participating centre

Queen's Medical Centre

Nottingham University Hospitals NHS Trust
Derby Road
Nottingham
United Kingdom
NG7 2UH

Study participating centre

Royal Devon and Exeter Hospital

Royal Devon and Exeter NHS Hospital Foundation Trust
Barrack Road
Exeter
United Kingdom
EX2 5DW

Study participating centre

Royal Surrey County Hospital

Royal Surrey County Hospital NHS Foundation Trust
Egerton Road
Guildford
United Kingdom
GU2 7XX

Study participating centre

Morriston Hospital

Heol Maes Eglwys
Morriston
Cwmrhydyceirw
Swansea
United Kingdom
SA6 6NL

Sponsor information

Organisation

Swansea University

Sponsor details

Research, Engagement and Innovation Services

Haldane Building

Singleton Campus

Swansea

Wales

United Kingdom

SA2 8PP

+44 (0)1792 513466

resgov@swansea.ac.uk

Sponsor type

University/education

Website

<http://www.swansea.ac.uk/>

ROR

<https://ror.org/053fq8t95>

Funder(s)**Funder type**

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Results will be published in a high impact peer-reviewed journal.

Intention to publish date

01/02/2025

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		17/08/2022	19/08/2022	Yes	No